Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PepGen (PEPG)

PepGen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PEPG
DateTimeSourceHeadlineSymbolCompany
07/11/202413:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
07/11/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
07/11/202413:00Business WirePepGen Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
04/11/202413:00Business WirePepGen to Participate in Upcoming Investor ConferencesNASDAQ:PEPGPepGen Inc
08/10/202412:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
08/10/202411:00Business WirePepGen Announces Presentations at the 29th Annual Congress of the World Muscle SocietyNASDAQ:PEPGPepGen Inc
19/09/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
19/09/202420:30Business WirePepGen Announces Christopher Ashton, PhD, to Retire from its Board of DirectorsNASDAQ:PEPGPepGen Inc
20/08/202420:05Business WirePepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & DevelopmentNASDAQ:PEPGPepGen Inc
20/08/202412:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
20/08/202412:00Business WirePepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & DevelopmentNASDAQ:PEPGPepGen Inc
08/08/202412:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
08/08/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
08/08/202412:00Business WirePepGen Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
30/07/202420:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
30/07/202420:02Business WirePepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
26/07/202420:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
19/07/202420:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
16/07/202420:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
09/07/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PEPGPepGen Inc
02/07/202412:00Business WirePepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate CommunicationsNASDAQ:PEPGPepGen Inc
13/06/202420:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
11/06/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
11/06/202411:00Business WirePepGen Announces Executive Team PromotionsNASDAQ:PEPGPepGen Inc
07/06/202420:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
05/06/202420:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PEPGPepGen Inc
18/05/202400:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
17/05/202420:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PEPGPepGen Inc
14/05/202420:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
14/05/202420:02GlobeNewswire Inc.PepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
 Showing the most relevant articles for your search:NASDAQ:PEPG